Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 6/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.96 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.96 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.96 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.96 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.73 |
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6602545 | 1.00 | LMNA (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29397565 | 1.00 | LMNA (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL6366499 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL29396943 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL379 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| Piperazine SCHEMBL28843777 | 0.96 | HTR3A (0.96) | LMNAMAPTHTR3ADRD2DRD3 | |
| Bromide SCHEMBL27797305 | 0.96 | HTR3A (0.96) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL9069817 | 0.95 | HTR3A (0.93) | LMNAMAPTHTR3ADRD2DRD3 | |
| Iodide SCHEMBL27505006 | 0.95 | HTR3A (0.93) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL253494 | 0.94 | LMNA (0.88) | LMNAMAPTHTR3ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038254-A | Serum 5 type haemophilus parasuis attenuated vaccine strain without antibiotic polygene deletion, construction method and application thereof | 河南省农业科学院畜牧研究所 | 2026-05-15 | — | — | CN | claimed |
| US-12510460-B2 | Method and apparatus for analyzing flow matrix data, and computer device | Hangzhou ShineDo Biotech. Co.Ltd. (CN) | 2025-12-30 | — | — | US | claimed |
| US-12359240-B2 | Membrane protease-based methods for detection of bacteria | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-07-15 | — | — | US | claimed |
| CN-119409858-A | Protonated product of pyridine derivative and compound, preparation method and application thereof | 天津师范大学 | 2025-02-11 | — | — | CN | claimed |
| EP-4386359-A1 | METHOD FOR ANALYZING FLOW MATRIX DATA, AND COMPUTER DEVICE | Hangzhou ShineDo Biotech. Co.Ltd. (CN) | 2024-06-19 | — | — | EP | claimed |
| US-20240192117-A1 | METHOD AND APPARATUS FOR ANALYZING FLOW MATRIX DATA, AND COMPUTER DEVICE | Hangzhou ShineDo Biotech. Co.Ltd. (CN) | 2024-06-13 | — | — | US | claimed |
| CN-118125995-A | Synthesis method of 1- (2-methoxyphenyl) piperazine hydrochloride | 南昌大学抚州医学院 | 2024-06-04 | — | — | CN | claimed |
| WO-2023229993-A1 | OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA | CURATIVE BIOTECHNOLOGY, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| CN-116693462-A | Preparation method of urapidil hydrochloride | 浙江皓华制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116496234-A | Preparation method of urapidil hydrochloride key intermediate | 江苏润安制药有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20220205015-A1 | MEMBRANE PROTEASE-BASED METHODS FOR DETECTION OF BACTERIA | NORTHWESTERN UNIVERSITY | 2022-06-30 | — | — | US | claimed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | claimed |
| CN-114478401-A | Preparation process of urapidil organic base raw material | 华裕(无锡)制药有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114057653-A | Preparation method of urapidil | 苏州新药篮生物医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-108329282-B | Phenylpiperazine derivative and preparation method and application thereof | 新乡医学院 | 2022-01-07 | — | — | CN | claimed |
| WO-2021050980-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-03-18 | — | — | WO | claimed |
| CN-101628899-A | 1-(2-methoxypheny1)-4-[3-(naphthalene-1-oxy)-2-hydroxypropyl] piperazine optical isomer and salt thereof, preparation method and application | GUANGZHOU MEDICAL COLLEGE | 2010-01-20 | — | — | CN | claimed |
| WO-2005021521-A1 | PREPARATION OF 1-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-3-(2,6-DIOXOPIPERIDIN-1-YL) PROPANE HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220205015-A1 | MEMBRANE PROTEASE-BASED METHODS FOR DETECTION OF BACTERIA | PDXK, PPOX, PCNP | HTR3A 542/4885DRD2 4293/4885DRD3 3535/4885 |
| US-12510460-B2 | Method and apparatus for analyzing flow matrix data, and computer device | MMP26, MMP16, MMP15 | HTR3A 2601/4885DRD2 4653/4885DRD3 4309/4885 |
| US-12359240-B2 | Membrane protease-based methods for detection of bacteria | PDXK, PPOX, PCNP | HTR3A 542/4885DRD2 4293/4885DRD3 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.